Transdermal Skin Patches Market Size, Share, Industry, Forecast and outlook (2024-2031)

Transdermal Skin Patches Market is Segmented By Type (Single-layer Drug-in-Adhesive, Multi-layer Drug-in-Adhesive, Vapour Patch, Matrix, Others), By Application (Pain Relief, Neurologic Conditions, Nicotine Cessation, Cardiovascular Conditions, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030 

Transdermal Skin Patches Market Report Overview

The Transdermal Skin Patches Market report analyzes the global market size, shares, recent trends, competitive intelligence, and future market outlook. Transdermal skin patches are medical patches that deliver medication through the skin for systemic distribution. They offer a convenient and non-invasive method of drug delivery and are commonly used for pain management, hormonal therapy, and nicotine replacement. The market is driven by the increasing prevalence of chronic diseases, the demand for non-oral drug delivery systems, and advancements in patch technology. In America, the Transdermal Skin Patches Market is witnessing significant growth. Key players in the market include Novartis AG, Johnson & Johnson, Mylan N.V., and other prominent players.

The transdermal patch is a type of transdermal technology. It's a medicated adhesive patch applied to the skin to give a specified medicine dose. These patches use a diffusion approach to deliver medicine doses through the skin, then released into the bloodstream over time. 

Transdermal Skin Patches Market Scope and Summary

For more insights - Download the Sample

Transdermal Skin Patches Market Dynamics and Trends

Advancement in transdermal drug delivery techniques is expected to drive market growth.

Microneedles (MNs) have evolved into a new drug delivery technology, with applications spanning small chemical molecules, vaccines, genes, proteins, and nanoparticles, among others. MNs, in particular, hold a lot of promise for the transdermal delivery of proteins and peptides. MNs are minimally invasive devices with needles (less than one millimeter) placed neatly on the base. They can directly permeate the stratum corneum by creating reversible microchannels in the epidermis. These microchannels allow medications to reach the dermal microcirculation, which is located in the skin's inner layers. MNs do not contact blood vessels or nerves in the deep dermis; hence they have a better patient compliance and safety profile than injections. Moreover, the mild fabrication condition of MNs will not impact the biological activity of proteins and peptides. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint

Some of the drawbacks of transdermal medication delivery are potential skin sensitivity or irritation, adhesive pain, imperfect skin adherence, cost, and selectivity for specific physicochemical drug features are some of the factors due to which the market is expected to get hampered in the forecast period.

COVID-19 Impact on Transdermal Skin Patches Market Growth

The COVID-19 pandemic had a positive impact on the market. The ongoing race to develop a safe and productive vaccine to prevent infection by SARS-CoV-2, the causative agent for COVID-19, highlights the importance of vaccination to combat infectious pathogens because the skin has a high density of antigen-presenting cells and immunological accessory cells with wide innate immune capabilities, the readily accessible cutaneous microenvironment is an ideal target for vaccination. For instance, Microarray patches (MAPs) are an appealing intracutaneous cargo delivery technology that allows for the safe, repeatable, and regulated distribution of vaccination components (antigens, with or without adjuvants) to specific skin microenvironments. Thus, this is owing to boost the transdermal skin patches market in the forecast period.

Transdermal Skin Patches Market Segment and Shares

The Nicotine Cessation segment is expected to hold the largest market share in the transdermal skin patches market

The nicotine cessation segment is expected to dominate in 2020. Cigarette smoking is not only the most frequent type of tobacco use, but it is also one of the main preventable risk factors for early mortality worldwide. According to the American Heart Association, cardiovascular disease accounts for about 800,000 U.S. deaths every year, making it the leading cause of death in the United States. Of those, nearly 20 percent are due to cigarette smoking. Moreover, according to the World Health Organization, in 2021, Over 80% of the world's 1.3 billion tobacco users will live in low- and middle-income nations. As a result, demand for transdermal skin patches (nicotine) is expected to rise during the forecast period, owing to the growing number of smokers worldwide.

Transdermal Skin Patches Market Geographical Analysis

North America region holds the largest market share in the global transdermal skin patches market

In 2020, North America accounted for the highest revenue share. The rising number of smokers, well-established healthcare infrastructure, beneficial government initiatives, and increased product launches and research collaborations by market players are some factors that the market is expected to boost in the forecast period. For instance, Tobacco is the largest cause of preventable disease and death in Canada, according to the Canadian Lung Association 2021. An estimated 48,000 Canadians die each year as a result of smoking. Countless others are afflicted with chronic ailments. Despite public health education and prevention efforts, approximately 15% of Canadians continue to smoke, increasing drug availability.

Moreover, in 2019, close to 2.9 million children started using e-cigarettes, or more than 7,900 per day. This increased from more than 2.2 million in 2018 and close to 2.1 million in 2017. Additionally, In September 2021, ImQuest Biosciences launched an antiretroviral (ARV) transdermal delivery patch. Therefore, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Transdermal Skin Patches Companies and Competitive Landscape

Major key players in the transdermal skin patches market are Teva Pharmaceuticals USA Inc., Novartis AG, Teikoku Pharma USA, Inc., Mylan Pharmaceuticals Inc., 3M, Luye Pharma Group, Sparsha Pharma USA, ProSolus, Inc., NITTO DENKO CORPORATION and Amarin Technologies.

Novartis AG:

Overview:

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is a publicly-traded Swiss holding company that operates through the Novartis Group. Novartis AG owns, directly or indirectly, all companies worldwide that operate as subsidiaries of the Novartis Group. Moreover, Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and the Pharmaceutical Research and Manufacturers of America (PhRMA). It is one of the largest pharmaceutical companies in the world. 

­Product Portfolio:

MyLab™9VET

Exelon Patch: Exelon Patch (rivastigmine transdermal system) is a reversible cholinesterase inhibitor used to treat mild to moderate dementia caused by Alzheimer's or Parkinson's disease.